Blood-based biomarkers have the potential to revolutionize clinical practice and clinical trials in Alzheimer disease (AD). However, to date, this “holy grail” opportunity has not been realized owing to a broad range of issues, including the lack of a clearly defined context of use (COU), lack of standardization of methods, and numerous failures at replication. Recently, however, a shift in the paradigm has occurred, with my colleagues and I proposing specific COUs for blood-based biomarkers along with potential paradigms for advancing from discovery to clinic and potential acceptable standards.1,2
O’Bryant SE. Blood Biomarkers for Use in Alzheimer Disease—Moving From “If” to “How?”. JAMA Neurol. 2019;76(9):1009–1010. doi:10.1001/jamaneurol.2019.0845
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: